Soft-tissue sarcomas are a heterogeneous group of malignant tumours of mesenchymal origin that originates from the soft tissues rather than bone.
They are classified on the basis of tissue seen on histology. 1 They account for less than 1% of all human tumors. Their biological behavior is characterized by local aggressiveness and tendency to hematogenous spreading. Almost 50% of STS patients develop metastatic disease, mainly within three years from initial diagnosis. The distribution of metastases from STS varies, depending on the primary site and histological subtype. For example, those arising from the extremities mainly spread to the lungs, and those arising from the abdominal cavity, usually metastasize to liver and peritoneum. 2 Even if no extensive data are currently available on the skeletal involvement in STS patients, the daily clinical practice suggests that the development of bone metastases causes pathological fracture, hypercalcemia and spinal cord compression. 3 The most common types of sarcoma in adults are undifferentiated pleomorphic sarcoma and bone metastases occur in almost 10% cases. Radiologically, bone metastases from STS are described as lytic in more than 80% of cases and the detection of a pathological fracture by radiography is not an uncommon finding. Diagnosis is confirmed by MRI features and biopsy (incisional biopsy, core biopsy or excisional biopsy). 4 The main types of treatment for soft tissue sarcoma are surgery, radiotherapy, chemotherapy and targeted therapy. Patients survive for a median of six months after diagnosis of bony involvement. 5 
